Fuller & Thaler Asset Management’s Puma Biotechnology PBYI Stock Holding History

Fuller & Thaler Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-600	Closed	-$114K	–	692
2014 Q4	$114K	Buy	600 +300	+100%	+$66.6K	﹤0.01%	468
2014 Q3	$72K	Buy	+300	New	+$61.6K	﹤0.01%	587
2014 Q2	–	Sell	-1,000	Closed	-$104K	–	666
2014 Q1	$104K	Buy	+1,000	New	+$118K	0.01%	623

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Fuller & Thaler Asset Management's PBYI Position: Q1 2015 in Review

Fuller & Thaler Asset Management sold out of Puma Biotechnology (PBYI) in Q1 2015, closing a stake of 600 shares — an estimated $114K sold.

Fuller & Thaler Asset Management first reported a position in PBYI in Q1 2014 and held it in 3 quarters. The position peaked at $114K in Q4 2014. 199 funds tracked by Wall St. Rank hold PBYI as of Q1 2015.

Fuller & Thaler Asset Management reported no remaining Puma Biotechnology position as of Q1 2015 after selling out during the quarter.
Fuller & Thaler Asset Management sold 600 Puma Biotechnology shares in Q1 2015, an estimated $114K.
Fuller & Thaler Asset Management first reported a position in Puma Biotechnology in Q1 2014 and held it in 3 quarters.
Fuller & Thaler Asset Management's Puma Biotechnology position peaked at $114K in Q4 2014.
199 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2015.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2015, filed 14 May 2015.